Compound class:
Synthetic organic
Comment: This compound is a particularly preferred example in patent US8664233 [1] which covers compounds for use in treating non-solid malignant hematological tumours, in particular, B cell leukemias.
|
|
Bioactivity Comments |
Patent US8664233 [1] does not directly measure the ability of this compound to inhibit PDE4B activity, but reports biologically relevant outputs such as apoptotic activity (activation of caspases 3, 7 and 9), cellular toxicity (IC50 80nM), and the substance's hemolytic effect. |